<DOC>
	<DOCNO>NCT01665846</DOCNO>
	<brief_summary>The purpose study describe radiologic finding brain MRI ferumoxytol administration HIV-infected patient cognitive impairment .</brief_summary>
	<brief_title>Ferumoxytol-enhanced Brain MRI HIV-associated Neurocognitive Disorders</brief_title>
	<detailed_description>The continue existence cognitive dysfunction HIV infect individual era effective antiretroviral therapy may , part , secondary failure current antiretroviral regimen eradicate pool HIV-infected activate monocyte within bloodstream . Trafficking HIV infect activated blood monocyte brain parenchyma believe introduce HIV brain precipitate immune activation inflammation , ultimately leading neuronal degeneration . Ferumoxytol ultrasmall superparamagnetic iron-oxide ( USPIO ) , FDA-approved intravenous iron-replacement therapy anemic patient chronic kidney disease . The paramagnetic property ferumoxytol also allow use MRI contrast agent . Ferumoxytol avidly take circulate monocyte reactive astrocyte , microglia , dendritic cell within brain , make potentially novel biomarker HIV-associated cognitive impairment give role monocyte pathogenesis . This proposal intend investigate possible use ferumoxytol ( new MRI contrast agent ) biomarker HIV-associated cognitive impairment ass safety tolerability ferumoxytol HIV-infected individual . Hypotheses test : - HIV-infected subject undetectable plasma HIV RNA level detectable level HIV DNA CD14+ peripheral blood mononuclear cell ( PBMCs ) impairment neurocognitive test demonstrate ferumoxytol contrast enhancement perivascular region brain consistent monocyte/macrophage infiltration region . - Ferumoxytol safely administer HIV-infected subject .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Neurocognitive Disorders</mesh_term>
	<mesh_term>AIDS Dementia Complex</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>HIV1 infection document ELISA confirm Western blot , HIV1 culture , HIV1 antigen , plasma HIV1 RNA RTPCR DNA time prior study entry . Receipt antiretroviral ( ARV ) medication uninterrupted least 6 month lead screen period demonstrate plasma HIV RNA &lt; 48 copies/ml within last 6 month . Willingness male females childbearing potential utilize 2 effective contraception method ( 2 separate form , one must effective barrier method ) , nonheterosexually active exclusive vasectomize partner screen throughout duration study treatment 30 day follow last dose study drug . Age &gt; 18 year . Ability willingness provide write informed consent HIV DNA &gt; 10 copies/106 CD14+ PBMCs Mild great cognitive impairment indicate global NPZ8 zscore &lt; 0.5 neurocognitive abnormality ( define zscore &lt; 0.5 ) least one cognitive domain characteristic HAD ( i.e. , executive function , psychomotor speed , memory ) . Requirement acute therapy AIDSdefining illness serious medical illness ( opinion site investigator ) within 14 day prior study entry . Known allergic hypersensitivity reaction FERAHEME , parental iron , parental dextran , parental irondextran , parental ironpolysaccharide preparation Known history iron overload syndrome ( e.g. , hereditary hemochromatosis , porphyria cutanea tarda ) Medical condition ( e.g. , chronic hemolytic anemia ) require frequent blood transfusion Taking oral iron supplementation Any factor precludes MRI scan include presence metal exposure metal work ( e.g . metal grinder/worker ) claustrophobia Past present HIV opportunistic infection brain , learn disability , head injury prolong loss consciousness cognitive sequela , nonHIV risk factor opinion principal investigator ( PI ) may impact cognitive performance . History epilepsy require treatment antiepileptic Other chronic illness include insulindependent diabetes , autoimmune disease , endocrinopathies , except subject stable physiologic replacement therapy low testosterone thyroid level Current active substance alcohol dependence positive urine toxicology screen . Pregnancy breastfeeding , intent become pregnant course study . Any condition , opinion investigator , would compromise subject 's ability participate study Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) great 2x upper limit normal preentry baseline laboratory safety assessment prior study enrollment . Elevated iron level preentry baseline laboratory safety assessment prior study enrollment . Hematocrit &gt; 52 % Hemoglobin &gt; 18 g/dL preentry baseline laboratory safety assessment prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>HIV associate neurocognitive disorder</keyword>
	<keyword>MRI</keyword>
	<keyword>Ferumoxytol</keyword>
</DOC>